Dr. Tara C. Gangadhar on Atypical Responses with Immunotherapies in Melanoma

Tara C. Mitchell, MD
Published: Thursday, Mar 03, 2016



Tara C. Mitchell, MD, assistant professor of Medicine, Perelman School of Medicine at the Hospital of the University of Pennsylvania, discusses atypical responses with immunotherapies in melanoma.

Compared to cytotoxic chemotherapy, responses can sometime be delayed with immunotherapy agents, says Mitchell.

On the first response assessment after immunotherapy, the tumor may appear larger or the same size as it was before treatment. This may be because the immunotherapy can take a longer time to work, or it could be due to immunotherapy-related inflammation in the tumor. This type of inflammation can sometimes look radiographically like a larger tumor, but a subsequent response assessment will reveal good tumor shrinkage and response, says Mitchell.
 


Tara C. Mitchell, MD, assistant professor of Medicine, Perelman School of Medicine at the Hospital of the University of Pennsylvania, discusses atypical responses with immunotherapies in melanoma.

Compared to cytotoxic chemotherapy, responses can sometime be delayed with immunotherapy agents, says Mitchell.

On the first response assessment after immunotherapy, the tumor may appear larger or the same size as it was before treatment. This may be because the immunotherapy can take a longer time to work, or it could be due to immunotherapy-related inflammation in the tumor. This type of inflammation can sometimes look radiographically like a larger tumor, but a subsequent response assessment will reveal good tumor shrinkage and response, says Mitchell.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Community Practice Connections™: 2nd Annual European Congress on Immunotherapies in Cancer™Jan 31, 20191.5
Publication Bottom Border
Border Publication
x